Hence, we started a systematic review of randomized controlled trials and observational trials to understand better the efficiency of SGLT2 inhibitors in providing protection from cardiovascular disorders and preventing renal adverse outcomes in individuals with T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.